More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. Clinical trials of the new compound on HIV-positive patients in Los Angeles and several other cities seemed to support their optimism. Patients needed just a fraction of the dose, …
Patients sue Gilead, saying drug company intentionally delayed safer HIV medicine
Via the LA Times By MELODY PETERSEN | MAY 09, 2018 | 5:00 AM Two Southern California men filed suit against Gilead Sciences on Tuesday, saying they were harmed when the drug company intentionally delayed development of a safer version of a crucial HIV medicine so that it could continue to profit from its lucrative monopoly. The lawsuit — and a …
‘Shameless’ Gilead Hikes Key AIDS Drug Pricing 6.9% Despite Recent Patent Expiration
As of January 2018, Gilead has raised the price of its HIV/AIDS treatments Truvada, Genvoya and Descovy 6.9%, despite the fact that the patent for tenofovir, a key component of all three treatments, expired in mid-December. In October, as patent expiration loomed, AHF called on Gilead for a 90% price reduction on its tenofovir-based drugs, including Truvada. Ethically challenged drug …
Gilead Lawsuits: California HIV Patients File Class Action and Personal Injury Cases Over Key HIV Drug
Legal actions filed by patients with HIV from Los Angeles, San Diego & Marin Counties target Gilead over its promotion of HIV/AIDS medication that causes permanent damage to the kidneys and bones AND over Gilead’s suppression of a safer version of the drug with far less toxicity in order to maximize profits and extend the sales of the initial drug, tenofovir …